Gynae BT 2017

First GOG#249 results

• Stage I-II HIR factors • Stage I-II serous / cc

Pelvic RT

R

3x carboplatin + paclitaxel + VBT

Completed accrual 2012 N=601, primary endpoint PFS

Update, median FU 53 months No difference RFS and Overall Survival

89% underwent lymphadenectomy 15% serous, 5% clear cell, 74% stage I

McMeekin, SGO 2014, Fleming, IGCS 2014; Randall ASTRO 2017